OUR FOUNDERS, TEAM & ADVISORS

Meet the experts behind our company

The founders of the company are dedicated to improve lives of patients with cardiovascular disease. They believe in the potential to prevent cardiovascular events like myocardial infarction, stroke, and death through combining state-of-the-art knowledge, analyzing big data cohorts from real-world evidence and applying artificial intelligence to identify the optimal treatment for each individual patient.

 

 

Our Advisors

Quick Link

CONTACT

Subscribe for Latest Articles and Resources

Copyright © 2022 tenacio

Dr Georg van Husen, MD

Co-founder and CEO

Georg is a Medical Doctor and has worked in a hospital cardiology unit before joining McKinsey & Co as a consultant where he focused on advising public and private payors, providers, and pharma companies. He then joined the pharmaceutical industry where he worked in various roles in Germany, the US and South Africa, before he became Global Senior Vice President for CardioMetabolism.

Georg is passionate about the opportunities through digital health to improve outcomes for patients with cardiovascular disease.

Prof Lord Ajay Kakkar, MD

Co-founder and Chairman

Ajay Kakkar is Director of the Thrombosis Research Institute, London and Professor of Surgery at University College London, Consultant Surgeon University College Hospitals NHS Foundation Trust, and Chair for Clinical Quality University College London Partners  Academic Health Science System. He received his medical education at King’s College Hospital Medical School, University of London, BSc 1985, MBBS (Hons) 1988, received a PhD in 1998 from Imperial College London. He was made a fellow of the Royal College of Surgeons of England in 1992.

Lord Kakkar is member of the House of Lords and was chairman of the House of Lords Appointment Committee from 2013 -2018.

Ajay has built the existing CV data cohort. His broad and highly recognized work in the area of CV research allows him to translate the data into meaningful results for business partners and patients.

Dr. Mathias Ottitsch

Chief Technology Officer

Mathias is a physicist by training and has spent his professional career in a number of different blue chip companies – from consulting to engineering, big tech and various start ups. With his experience in scaling companies in executive roles as Chief Operating Officer and Chief Platform Officer he is now building the technology platform for tenac.io and drivers our AI and ML development.

Professor Keith AA Fox, BSc MB ChB, MRCP, FRCP, FESC, FMedSci, FACC

Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Professor of Cardiology at the University of Edinburgh and British Heart Foundation Professor of Cardiology (Emeritus)

Previously Assistant Professor of Internal Medicine and Cardiology at Washington University School of Medicine, and Senior Lecturer in Cardiology, at the University of Wales. Head of the Division of Medical and Radiological Sciences of the University of Edinburgh, Duke of Edinburgh and British Heart Foundation Professor of Cardiology, and Consultant Cardiologist at the Royal Infirmary of Edinburgh.

Founding fellow of the European Society of Cardiology (ESC) and prior President of the British Cardiovascular Society and former Chair of the Scientific Programme of the ESC.
He is the recipient of various awards, including the Silver and Gold Medals of the European Society of Cardiology. He was honoured by the American College of Cardiology and by the European Society of Cardiology as one of the “Legends in Cardiology”.

Winner (with colleagues) of the Queen’s Anniversary Prize (for Science and Medicine 2016). He is the author of more than 710 scientific papers. Thompson Reuters listed him as one of the top 1% of scientists as ‘the World’s Most Influential Scientific Minds.

Professor Christopher Granger

Dr. Christopher Granger is a Professor of Medicine in the Division of Cardiology at Duke University Medical Center. He is an non-interventionist and his primary patient work is focused on CICU patient care.  He serves on the editorial boards of several cardiology journals.  He is a member of the ACCF/AHA STEMI Guidelines Committee and the AHA/ACC/HRS Guideline for the Management of Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.  Dr. Granger’s primary research interest is in the conduct and methodology of large randomized clinical trials in heart disease.

Karen Pieper, MSc Biostatistics

Thrombosis Research Institute, London, UK

Global Director of Statistical Sciences and Communications at Thrombosis Research Institute and President of Pieper Consulting, LLC. She has been a statistician in the field of cardiovascular research for around 35 years. She has worked with the Duke Database for Cardiovascular Disease, the University of Virginia department of Biostatistics, Pieper Statistical Consulting, and primarily with the Duke Clinical Research Institute (DCRI) where she was an Associate Director of Clinical Trials Statistical Operations.  She retired from DCRI in 2019.  Currently, she works with the Thrombosis Research Institute as well as functions as the statistician on multiple data and safety monitoring boards and executive committees.

Karen Pieper has served as the statistical reviewer for multiple high impact clinical and statistical journals, and as a previous member of the American Statistical Association committees for Ethics and for Applied Statistics.  She is a recognized leader in teaching.  DCRI created the “Karen Pieper Award” for mentorship and support to recognize her work in training clinical fellows.  She has presented at numerous conferences and has been a speaker on research methods at workshops and training sessions across several countries.  

Annalisa Jenkins, M.B.B.S., F.R.C.P.

Annalisa Jenkins is a biopharma thought leader with over 25 years of industry experience. Dr. Jenkins has extensive recent experience in building and financing biotech companies pursuing cures for the most challenging rare diseases. She has consistently built and led teams advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. In addition, she is an advocate for diversity and inclusion, particularly for women in science. Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years – including serving as senior vice president and head of global medical affairs. She also is a trustee for The King’s Fund, a medical trustee for the British Heart Foundation, a committee member of the Science Board to the U.S. Food & Drug Administration, an advisory board member at FasterCures – a center of The Milken Institute – and Chair of The Court The London School of Hygiene and Tropical Medicine.